Inflazome to be Granted Patents in US and Europe
Inflazome, a biotech company based in Dublin, Ireland, has announced that the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) will grant its patent applications in January 2020.
Inflazome, a biotech company based in Dublin, Ireland, has announced that the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) will grant its patent applications in January 2020.
According to a Jan. 13, 2020 press release, the company revealed that its US patent will be granted on Jan. 21, 2020 and its European patent was granted on Jan. 15, 2020. The patents cover compounds that have been shown to be useful in the inhibition of NLRP3 inflammasome activation.
With these latest patents, the company has extended and strengthened its intellectual property (IP) portfolio. Currently, the company has 43 patent families.
“The granting of these pioneering patents marks another milestone for Inflazome and strengthens our IP portfolio,” said Matt Cooper, CEO of Inflazome, in the press release. “The patents granted in the US and Europe cover our lead clinical candidate, Inzomelid. Both Inzomelid and our second drug, Somalix, are in the final stages of Phase I safety and tolerability trials for inflammatory diseases. We look forward to driving these drugs into further trials to help people with debilitating diseases.”
Source: Inflazome
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
